125 related articles for article (PubMed ID: 17668540)
21. Open label trial of alefacept in palmoplantar pustular psoriasis.
Carr D; Tusa MG; Carroll CL; Pearce DJ; Camacho F; Kaur M; Cook C; Willard J; McCarty A; Fleischer AB; Liu CM; Goffe BS; Feldman SR
J Dermatolog Treat; 2008; 19(2):97-100. PubMed ID: 18512272
[TBL] [Abstract][Full Text] [Related]
22. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum.
Foss CE; Clark AR; Inabinet R; Camacho F; Jorizzo JL
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):943-9. PubMed ID: 18384543
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
[TBL] [Abstract][Full Text] [Related]
26. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
27. The AWARE study: methodology and baseline characteristics.
Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
[TBL] [Abstract][Full Text] [Related]
28. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
Ortonne JP; Prinz JC
Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
[TBL] [Abstract][Full Text] [Related]
29. Failure of alefacept in the treatment of vitiligo.
Bin Dayel S; AlGhamdi K
J Drugs Dermatol; 2013 Feb; 12(2):159-61. PubMed ID: 23377387
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
31. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases.
Thaçi D; Pätzold S; Kaufmann R; Boehncke WH
Br J Dermatol; 2005 May; 152(5):1048-50. PubMed ID: 15888169
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
[TBL] [Abstract][Full Text] [Related]
33. Monitoring patients treated with efalizumab or alefacept.
Papp KA
Curr Probl Dermatol; 2009; 38():95-106. PubMed ID: 19710552
[TBL] [Abstract][Full Text] [Related]
34. Treatment of palmoplantar psoriasis with intramuscular alefacept.
Myers W; Christiansen L; Gottlieb AB
J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
[TBL] [Abstract][Full Text] [Related]
35. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
37. Alefacept treatment for chronic plaque psoriasis.
Dunn LK; Feldman SR
Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167
[TBL] [Abstract][Full Text] [Related]
38. Possibilities of using alefacept in the treatment of psoriasis.
Pietrzak A; Chodorowska G; Bartkowiak-Emeryk M; Pietrzak B; Urban J; Juszkiewicz-Borowiec M; Miturska R
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):311-3. PubMed ID: 15323211
[TBL] [Abstract][Full Text] [Related]
39. Alefacept: potential new therapy for patients with moderate-to-severe psoriasis.
Shukla VK
Issues Emerg Health Technol; 2003 Apr; (45):1-4. PubMed ID: 12680422
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
